Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–105 of 105 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Adenosine arm Clear all

Conditions: Muscle Fatigue Caused by Repetitive Muscle Exercise
Interventions: Placebo, ATP; Dietary Supplement
Lead sponsor: Metabolic Technologies Inc.; Industry
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Sickle Cell Anemia
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 10 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Breast Cancer
Interventions: Docetaxel, Pertuzumab, Trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Charlotte, North Carolina • Houston, Texas

Conditions: Neoplasms
Interventions: Niraparib, Pembrolizumab, TSR-042 (Dostarlimab); Drug · Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 16
States / cities: Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more

Conditions: Breast Cancer
Interventions: Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 22
States / cities: Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more

Conditions: HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
Interventions: Palbociclib, T-DM1; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more

Conditions: Advanced Unresectable or Metastatic Solid Malignancy
Interventions: Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 38
States / cities: Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more

Conditions: Arthrogryposis, Craniofacial Abnormalities
Interventions: Lactate, Glucose, and Adenosine Triphosphate Blood Levels, Physiological Stress Test, Functional Enquiry Form, Strength, Joint ROM, Girth and Length Measurements, Study Physical Examination, Observational Gait Analysis, Mental Health Interview; Other · Procedure
Lead sponsor: Freeman-Sheldon Research Group, Inc.; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Buckhannon, West Virginia

Conditions: Ovarian Neoplasms
Interventions: Niraparib, Bevacizumab; Drug · Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 29
States / cities: Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more

Search by objective public record fields.

Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout

A Phase II Trial of Regadenoson in Sickle Cell Anemia

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy